Danny Khalil, MD, PhD

I am a board-certified medical oncologist who specializes in caring for people with hepatobiliary, colorectal, pancreatic, and other gastrointestinal cancers. As a member of the MSK Immunotherapeutics Clinic and the Parker Institute for Cancer Immunotherapy, I am involved in the range of cancer immunotherapy research from basic science to clinical trials.

For a cancer to exist in the body it must be able to evade destruction by the immune system.  Some cancers do this by triggering signals that inhibit immunologic activity.  Medicines that interfere with this type of signalling have now led to dramatic tumor regressions for many cancer patients.  My work is focused on identifying and blocking signals that instruct the immune system to tolerate cancer.

• Memorial Sloan Kettering Cancer Center, Fellowship, Medical Oncology
• New York-Presbyterian/Weill Cornell Medical College, Residency, Internal Medicine
• Stony Brook University, Cold Spring Harbor Laboratory, New York, MD, PhD

• American Society of Clinical Oncology Young Investigator Award, Conquer Cancer Foundation
• Daland Fellowship in Clinical Investigation, American Philosophical Society
• American Association for Cancer Research Amgen Clinical Translational Cancer Research Fellowship
• US Department of Defense, Congressionally Directed Medical Research Programs Prostate Cancer Training Award